Estados Unidos · Bolsa y Finanzas · Yahoo Finance

Iambic Therapeutics (IAM) Filed An IND For IAM217

Publicado por Yahoo Finance · Estados Unidos hace 9 h

Iambic Therapeutics (NasdaqGS:IAM) submitted an Investigational New Drug application to the FDA for IAM217, a KIF18A inhibitor, in October 2026. IAM217 is described by the company…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

Iambic Therapeutics (IAM) Filed An IND For IAM217

También te puede interesar

Tether backs AIsa as strategic investor, completing seed extension round

Why hedge funds could be making a bond market shock more likely

Americans are packing town halls to stop data centers. It's working, for now

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

New England faces record-high heating oil costs this winter

Iambic Therapeutics (IAM) Filed An IND For IAM217

Compartir

También te puede interesar

Tether backs AIsa as strategic investor, completing seed extension round

Why hedge funds could be making a bond market shock more likely

Americans are packing town halls to stop data centers. It's working, for now

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

New England faces record-high heating oil costs this winter